A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. Issue 12 (15th October 2021)

• Record Type: Journal Article
• Authors: Liu, Lawrence; Fiala, Mark; Gao, Feng; King, Justin; Goldsmith, Scott; Wildes, Tanya M.; Stockerl-Goldstein, Keith; Vij, Ravi; Schroeder, Mark A.
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 12(2021)
• Page Start: 3043
• Page End: 3046
• Publication Date: 2021-10-15
• Subjects: Myeloma -- antibody-based immunotherapy -- chemotherapeutic approaches -- cytogenetics -- drug resistance -- immunotherapy; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1941940
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Daratumumab, pomalidomide, and dexamethasone (DPd) is an FDA-approved 3rd or later line of therapy for myeloma. However, as there are limited published data on the efficacy of 2nd-line DPd, we conducted a retrospective analysis ( n = 33). Herein, we report our center's data for 2nd-line DPd. Our patient population had a high amount of high risk cytogenetics (45.5%). The overall response rate (ORR) was 84.9% with a 1-year Progression Free Survival (PFS) of 37.7%. In standard risk myeloma ( n = 18), the ORR was 88.9% and 1-year PFS was 61.1% (95% CI 42.3–88.3%). In high risk myeloma (45.5%, n = 15), the ORR was 80% with a 1-year PFS of 7.3% (95% CI 1.1–47.9%). This suggests that the efficacy of 2nd-line DPd in myeloma with high risk cytogenetics should be further investigated.